NASDAQ
STLNW
Last Price
US $0.0552
Valuation
Financial
Performance
Cash flow to debt coverage
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst balance-sheet data unavailable; cash-flow debt coverage cannot be computed.
Free cash flow growth
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Debt-to-equity ratio
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Debt-to-equity trend
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Net debt to EBITDA
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has negative EBITDA, making leverage ratio unreliable
Interest coverage
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Profit margin growth
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Current ratio
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Return on assets
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst's return on assets of -20.36% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst's return on equity of 209.81%, is higher than 15.00%, indicating good performance
Earnings quality
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Earnings stability
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Revenue growth
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Return on invested capital
ROIC -28.82% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to evaluate this check.
Earnings yield (TTM)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
EBITDA Valuation
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has insufficient data to calculate the PEG ratio.
Price-to-book ratio (FY)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst has a price-to-sales ratio of 0.01x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $0.0552
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.